Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Fiche publication
Date publication
février 2016
Journal
Lancet (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HERBRECHT Raoul
Tous les auteurs :
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ
Lien Pubmed
Résumé
Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease.
Mots clés
Administration, Oral, Adult, Aged, Antifungal Agents, administration & dosage, Aspergillosis, drug therapy, Double-Blind Method, Drug Administration Schedule, Female, Humans, Injections, Intravenous, Male, Middle Aged, Mycoses, drug therapy, Nitriles, administration & dosage, Pyridines, administration & dosage, Treatment Outcome, Triazoles, administration & dosage, Voriconazole, administration & dosage
Référence
Lancet. 2016 Feb;387(10020):760-9